ARTELO BIOSCIENCES INC ARTL 深 滬
已收盤 09-05 16:00:00 美东时间
4.51
+0.160
+3.68%
華盛通- 最 高4.70
- 今 開4.48
- 成交量 23.51万股
- 最 低 4.30
- 昨 收 4.35
- 總市值 246.61万
- 52周最高 28.60
- 市盈率 靜 --
- 換手率 42.99%
- 52周最低 4.20
- 委 比 -89.96%
- 總股本 54.68万
- 歷史最高 450.00
- 量 比 1.10
- 振 幅 9.20%
- 歷史最低 4.30
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
Artelo Biosciences, a clinical-stage pharmaceutical company, has priced its public offering of 640,924 shares of common stock at $4.40 per share and pre-funded warrants for up to 40,894 shares at $4.399 per warrant. The offering is expected to raise approximately $3.0 million in gross proceeds. Underwriters have a 45-day option to purchase an additional 102,272 shares. The offering is expected to close on September 5, 2025, subject to customary c...
09-04 12:37
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Artelo Biosciences launches public offering; shares down 10%
Artelo Biosciences (NASDAQ:ARTL) has commenced an underwritten public offering of common stock and/or pre-funded warrants. All securities in the offering will be sold by the company itself. The size, ...
09-04 04:50
Artelo Biosciences Announces Interim Results From Phase 2 CAReS Trial With ART27.13, Peripherally Acting Cannabinoid Receptor Agonist For Treatment Of CACS
Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACSConsistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients
09-03 20:47
Artelo Biosciences Announces Proposed Underwritten Public Offering
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on developing therapeutics targeting lipid-signaling pathways for conditions like cancer, pain, and dermatologic diseases, has announced the commencement of an underwritten public offering of its common stock and/or pre-funded warrants. The offering is subject to market conditions, and there is no assurance of completion, size, or terms. R.F. Lafferty & Co., ...
09-03 20:35
Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results
<p>Artelo Biosciences, Inc. announced positive interim results from its Phase 2 CAReS trial for ART27.13, a novel drug targeting peripheral CB1 and CB2 receptors, showing significant improvements in weight, lean body mass, and activity in cancer patients with anorexia-cachexia syndrome (CACS). With strong interest from multiple pharmaceutical companies, Artelo is positioning to secure a development partner to advance ART27.13 through Phase 3 tria...
09-03 15:33
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
Artelo Biosciences announced interim results from its Phase 2 CAReS trial for ART27.13, showing significant improvements in weight, lean body mass, and activity in cancer patients with anorexia-cachexia syndrome (CACS). Patients on ART27.13 gained an average of 6.38% body weight vs. a 5.42% loss on placebo. The drug was well-tolerated with mild to moderate side effects. These results support further development and potential partnerships for ART2...
09-03 12:45
Artelo Biosciences Approves Common Stock Increase
An update from Artelo Biosciences ( ($ARTL) ) is now available. On August 28, 2...
08-30 04:58
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
Artelo Biosciences provided a business update for Q2 2025, highlighting clinical progress across its pipeline: - ART26.12: Phase 1 SAD study completed with positive safety results; MAD study planned for Q4 2025. Data presented at the British Pain Society Conference supports its potential for osteoarthritis and mood disorders. - ART27.13: Phase 2 CAReS study in cancer anorexia-cachexia syndrome expected to report data in Q3 2025; safety demonstra...
08-13 12:00
